Discussion
The first patient has been dosed in a Phase 2a clinical trial evaluating Jotrol, an investigational oral formulation of resveratrol that Jupiter Neurosciences is developing for Parkinson’s disease. The trial is expected to be completed in the first half of 2029. The RESET trial (NCT07592767) is enrolling…
